Lupin Limited, a leading global pharmaceutical company, announced today that the United States Food and Drug Administration (U.S. FDA) has successfully completed a Good Manufacturing Practice (GMP) Inspection of its…
The Hague, April 10, 2024—In a significant milestone for their enduring partnership, the World Health Organization (WHO) and the Netherlands convened to discuss shared priorities and the alignment of strategic…
In a groundbreaking development, Nigeria has emerged as the global pioneer in introducing a new vaccine, known as Men5CV, endorsed by the World Health Organization (WHO). This innovative vaccine provides…
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has revealed that its expansive neuroscience portfolio and pipeline will be prominently featured at the 76th Annual American Academy of Neurology Meeting (AAN), taking place…
Shionogi B.V., the European arm of Shionogi & Co., Ltd., has revealed that the European Commission has granted Orphan Medicinal Product designation to zatolmilast (BPN14770), an investigational treatment for Fragile…
Baxter International Inc. (NYSE:BAX), renowned globally for its excellence in injectables, anesthesia, and drug compounding, has unveiled a significant expansion of its Pharmaceuticals portfolio with the introduction of five new…
Today, Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced an anticipated booking of approximately ¥70.0 billion in the fourth quarter of fiscal year 2023. This booking…
As the daughter of immigrants, Gabriela Ziccarelli, PharmD, BCACP, is deeply committed to reducing health disparities, particularly among minority communities. With nearly two decades at Walgreens, she has dedicated much…
Novartis has officially released the offer document for its subsidiary, Novartis BidCo AG’s, voluntary public takeover bid for all outstanding shares of MorphoSys AG, inclusive of MorphoSys American Depositary Shares…
Roche (SIX: RO, ROG; OTCQX: RHHBY) disclosed today that its Elecsys pTau217 assay has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). Developed in collaboration…
AbbVie (NYSE: ABBV) has revealed interim findings from an ongoing Phase 3 extension study, spanning 156 weeks, investigating the sustained safety and tolerability of oral atogepant for migraine prevention in…
Mira Leppänen-Mattelmäki, a Research Associate in Orion’s pain team, finds her greatest motivation in the potential impact their work may have on patients. For Minna Vuorenmaa, a Research Assistant in…